Because bacterial toxins such as LPS produced by Gram-negative bacteria can damage the gut and blood-brain barriers, which are the two major gateways to autoimmune, neuroinflammatory, neurodegenerative, and neuropsychiatric disorders, we conclude that patients with IBD should be screened for LPS IgG, IgM, and IgA antibodies and their correlation with barrier protein antibodies in an effort to prevent BBB damage and its neurologic comorbidities. The gene discussed is CD79A; the disease is irritable bowel syndrome.